Rapid, automated, parallel quantitative immunoassays using highly integrated microfluidics and AlphaLISA.
Zeta Tak For Yu1, Huijiao Guan1, Mei Ki Cheung1
1Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan 48109, USA.
Scientific Reports
|June 16, 2015
Summary
A novel microfluidic immunoassay chip automates sample analysis using AlphaLISA technology. This high-throughput platform enables rapid, parallel detection of biomolecules in multiple samples, improving diagnostic potential.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Immunotechnology
Background:
- Immunoassays are crucial for biomolecule detection but traditional methods like ELISA are labor-intensive and prone to error.
- Current immunoassays face limitations in speed, automation, and suitability for standardized clinical diagnostics.
- There is a need for rapid, automated, and high-throughput immunoassay platforms for clinical applications.
Purpose of the Study:
- To develop a microfluidic immunoassay chip for rapid, automated, and parallel detection of biomolecules.
- To integrate AlphaLISA homogeneous immunoassay technology with microfluidics for enhanced performance.
- To evaluate the chip's capabilities for quantitative immunosensing and functional immunophenotyping.
Main Methods:
- Development of a microfluidic chip integrating AlphaLISA technology for no-wash, homogeneous immunoassays.
- Automated fluid handling, surface passivation, and quantitative imaging for simultaneous analysis of up to eight samples.
- Investigation of operational parameters including fluid handling, surface passivation, imaging uniformity, and detection sensitivity.
Main Results:
- The microfluidic immunoassay chip achieved rapid, automated, parallel detection of analytes in microliter samples within 45 minutes.
- A limit of detection as low as 10 pg mL(-1) was achieved for a single target analyte across eight samples.
- The chip was successfully applied to functional immunophenotyping by examining cytokine secretion from ex vivo stimulated human immune cells.
Conclusions:
- The developed microfluidic immunoassay chip offers a promising high-throughput platform for quantitative immunosensing.
- This technology enables rapid, automated, and parallel immunoassays, overcoming limitations of conventional methods.
- The chip has significant potential for diverse applications in clinical diagnostics and biomedical research.
